Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First sale of TexRAD in China

9 Sep 2015 07:00

RNS Number : 4455Y
Feedback PLC
09 September 2015
 

9 September 2015

 

Feedback plc

("Feedback" or the "Company")

 

First sale of TexRAD in China

 

 

Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce the first sale for research purposes of Feedback's TexRAD texture analysis software in China. Peking Union Medical College Hospital ("PUMCH"), Beijing, China, has recently purchased the TexRAD software to undertake research studies in cancer and other diseases. This has been made possible via logistical support from GE Healthcare ("GE").

 

PUMCH is one of the most renowned hospitals in the People's Republic of China. It was founded in 1921 by the China Medical Board in New York under the Rockefeller Foundation and is located in the centre of modern Beijing. PUMCH is committed to delivering state-of-the-art clinical care, innovative scientific research and rigorous medical education and it enjoys a high reputation for its full range of disciplines, leading medical practitioners and cutting-edge technologies. It is also a national referral centre for the diagnosis and therapeutic care of complex and rare disorders.

 

Dr. Huadan (Danna) Xue, Assistant Professor in the Department of Radiology, PUMCH commented, "We are very excited with the prospects of using the TexRAD imaging research software platform in conjunction with the research and clinical support from GE towards PUMCH, further reinforcing our vision and reputation of being early adopters of new technologies, particularly in the fascinating area of quantitative imaging and its applications in cancer care and other diseases."

 

TexRAD research software will extract key heterogeneity information via a novel quantitative texture analysis approach from PUMCH's cancer imaging datasets. TexRAD has already established itself as a leading and innovative texture analysis software product, currently employed as a research tool in a number of prestigious imaging centres and university hospitals in the western world and recently in other large Asian markets such as South Korea and Japan. Similarly at PUMCH, TexRAD will be assisting to enhance the research output in cancer and other non-cancer imaging applications and helping to identify potential clinical applications to improve care management of patients in the future.

 

Dr. Balaji Ganeshan, Chief Scientist and New Business Officer at the Company's subsidiaries TexRAD Ltd and Cambridge Computed Imaging Ltd, commented, "We are delighted to receive this order, working with a leading original equipment manufacturer on the sale and entering the huge Chinese market. We are especially privileged to be supplying PUMCH which is recognized to be the leading hospital in China and working with the Department of Radiology, headed by the internationally renowned Dr Zheng-Yu Jin. We believe this will open up new avenues and opportunities for Feedback in establishing itself and fulfilling its vision as an innovative multi-modality medical imaging software company."

 

For further information contact:

 

Feedback plc

Tel: 01954 718072

Simon Barrell / Trevor Brown / Tom Charlton

Sanlam Securities UK (Nominated Adviser and Joint Broker)

 Tel: 020 7628 2200

Simon Clements / Virginia Bull

Peterhouse Corporate Finance Ltd (Joint Broker)

Tel: 020 7469 0936

Lucy Williams / Duncan Vasey

 

Notes to editors:

 

TexRAD (is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than it is currently possible to see with the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging-Biomarker') in confident decision-making: assessing the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'.TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUWRSRVWAKRAR
Date   Source Headline
25th Mar 20247:00 amRNSNew tuberculosis partnership in India
21st Mar 20247:00 amRNSFurther CDC Pilot Programme Secured
23rd Feb 202411:03 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSHalf-year Report
21st Feb 20247:00 amRNSMedical Imaging Partnership Pilot Agreement
6th Feb 20247:00 amRNSNotice of Results & Investor Presentation
19th Dec 20237:01 amRNSHalf Year Trading Update
19th Dec 20237:00 amRNSAward of Pilot Funding
26th Oct 20232:24 pmRNSResult of AGM
25th Oct 20235:53 pmRNSDirector Dealing
27th Sep 202312:15 pmRNSNotice of AGM
12th Sep 20237:00 amRNSFinal Results
5th Sep 20237:00 amRNSNotice of Results & Investor Presentation
19th Jun 20237:00 amRNSYear End Trading Update
4th Apr 20237:00 amRNSBleepa-CareLocker contract extension with QVH
7th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:56 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSNotice of Results, Analyst & Investor Presentation
22nd Dec 202212:08 pmRNSDirector/PDMR Shareholding: Correction
22nd Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20227:00 amRNSHalf Year Trading Update
1st Nov 20223:36 pmRNSTotal Voting Rights
13th Oct 20222:55 pmRNSResult of AGM & Proposed Share Consolidation
29th Sep 20223:46 pmRNSHolding(s) in Company
20th Sep 20223:26 pmRNSNotice of AGM & Proposed Share Consolidation
20th Sep 20227:00 amRNSFinal Results
13th Sep 20227:00 amRNSNotice of Results & Investor Presentation
6th Sep 20227:00 amRNS12 month contract for Sussex CDC pilot extension
19th Jul 20227:00 amRNSContract Update
16th Jun 20227:00 amRNSYear End Trading Update
1st Jun 20227:00 amRNSTrading Update & Director Appointment
12th May 202212:44 pmRNSChange of Registered Office
12th Apr 20227:00 amRNSBleepa wins two NHS Contract Awards
31st Mar 20227:00 amRNSBleepa TB Screening Pilot Now Live in Odisha
23rd Feb 20227:00 amRNSGrant of Options and PDMR dealing
10th Feb 20227:00 amRNSInterim Results
31st Jan 20227:00 amRNSNotice of Results
13th Dec 20217:00 amRNSPartnership with Amazon Web Services
6th Dec 20213:06 pmRNSHolding(s) in Company
2nd Dec 202110:20 amRNSDirector/PDMR Shareholding
2nd Dec 20219:54 amRNSHolding(s) in Company
1st Dec 20214:27 pmRNSHolding(s) in Company
1st Dec 20213:09 pmRNSHolding(s) in Company
30th Nov 20214:05 pmRNSHolding(s) in Company
29th Nov 20211:36 pmRNSDirector Appointment
29th Nov 20211:35 pmRNSResults of AGM, Open Offer, Issue of Equity & TVR
18th Nov 202112:15 pmRNSHolding(s) in Company
16th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20211:52 pmRNSResult of Placing
2nd Nov 20217:01 amRNSProposed Placing and Open Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.